Association of upper and lower airway eosinophilic inflammation with response to omalizumab in patients with severe asthma
Authors:
- 2 January 2020
- journal article
- research article
- Published by Taylor & Francis in Journal of Asthma
- Vol. 57 (1) , 71-78
Abstract
Background: The anti-immunoglobulin E monoclonal antibody, omalizumab, is used to treat severe asthma and has the potential to ameliorate airway inflammation. However, the effect of omalizumab in ameliorating upper airway inflammation has not been fully elucidated. Objective: We investigated the association of upper and lower airway inflammation with the response to omalizumab treatment. Methods: We used the Global Evaluation of Treatment Effectiveness to assess the efficacy of omalizumab in treating 16 patients with severe asthma. We also investigated the symptom score, short-acting beta-agonist inhaler use, pulmonary function, biomarkers, computed tomography scans, and nasal mucosa pathology at omalizumab initiation and after four months of treatment. Results: When the fraction of exhaled nitric oxide (FeNO) and the percentage of sputum eosinophil were used as indicators of lower airway inflammation, positive correlations were found between CD20 B-cell, mast cell, and eosinophil counts in the nasal mucosa. Improved asthma symptoms were observed in 12 of the 16 severe asthma cases. The FeNO and eosinophil levels in the nasal tissue, prior to the administration of omalizumab were predictors of the response to asthma treatment. Conclusions: These findings suggest heterogeneity among people with severe asthma. In addition, the phenotype associated with response to omalizumab, leading to improvement in asthma symptoms, comprises upper airway eosinophilia and high FeNO levels.Keywords
This publication has 22 references indexed in Scilit:
- Persistency of response to omalizumab therapy in severe allergic (IgE-mediated) asthmaAllergy, 2011
- Efficacy and safety of omalizumab in an Asian population with moderate‐to‐severe persistent asthmaRespirology, 2009
- Allergic Rhinitis and its Impact on Asthma (ARIA) 2008*Allergy, 2008
- Predicting and evaluating response to omalizumab in patients with severe allergic asthmaRespiratory Medicine, 2007
- The anti-inflammatory effects of omalizumab confirm the central role of IgE in allergic inflammationJournal of Allergy and Clinical Immunology, 2005
- Benefits of omalizumab as add‐on therapy in patients with severe persistent asthma who are inadequately controlled despite best available therapy (GINA 2002 step 4 treatment): INNOVATEAllergy, 2004
- Omalizumab-induced reductions in mast cell FcεRI expression and functionJournal of Allergy and Clinical Immunology, 2004
- Does Exhaled Nitric Oxide Reflect Asthma Control?American Journal of Respiratory and Critical Care Medicine, 2001
- Pathophysiology of severe asthmaJournal of Allergy and Clinical Immunology, 2000
- Eosinophils are a feature of upper and lower airway pathology in non‐atopic asthma, irrespective of the presence of rhinitisClinical & Experimental Allergy, 2000